Page last updated: 2024-11-07

prednisone and Orthopedic Disorders

prednisone has been researched along with Orthopedic Disorders in 7 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
"Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease."	1.51	Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019)

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	4 (57.14)	29.6817
2010's	1 (14.29)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Adami, G	1
Fassio, A	1
Rossini, M	1
Benini, C	1
Pistillo, F	1
Viapiana, O	1
Bertelle, D	1
Gatti, D	1
Groot, N	1
Shaikhani, D	1
Teng, YKO	1
de Leeuw, K	1
Bijl, M	1
Dolhain, RJEM	1
Zirkzee, E	1
Fritsch-Stork, R	1
Bultink, IEM	1
Kamphuis, S	1
Stoll, T	1
Sutcliffe, N	1
Mach, J	1
Klaghofer, R	1
Isenberg, DA	1
Cutler, C	1
Miklos, D	1
Kim, HT	1
Treister, N	1
Woo, SB	1
Bienfang, D	1
Klickstein, LB	1
Levin, J	1
Miller, K	1
Reynolds, C	1
Macdonell, R	1
Pasek, M	1
Lee, SJ	1
Ho, V	1
Soiffer, R	1
Antin, JH	1
Ritz, J	1
Alyea, E	1
Grunwald, MH	1
Amichai, B	1
Friedman, RJ	1
Schiff, CF	1
Bromberg, JS	1
Ancín, I	1
Ferrá, C	1
Gallardo, D	1
Peris, J	1
Berlanga, J	1
Gonzalez, JR	1
Virgili, N	1
Grañena, A	1

Clinical Trials (6)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Validation of the SLEDAI-P Self-questionnaire Completed by the Patient to Measure the Activity of the Systemic Lupus[NCT05763225]		500 participants (Anticipated)	Observational	2023-04-30	Not yet recruiting
An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease[NCT00136396]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2004-01-31	Completed
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2019-04-11	Terminated (stopped due to Insufficient accrual)
Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease[NCT01161628]	Phase 2	25 participants (Actual)	Interventional	2011-04-30	Completed
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610]	Phase 2	78 participants (Actual)	Interventional	2011-11-30	Active, not recruiting
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease[NCT06046248]	Phase 2	25 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

Intervention	Participants (Count of Participants)
Ibrutinib Plus Rituximab	0

Duration of Systemic Corticosteroid Use

(NCT01161628)
Timeframe: 2 years

Intervention	days (Median)
Rituxan	15

Incidence of Disease-free Survival

(NCT01161628)
Timeframe: 2 years

Intervention	percentage of patients (Number)
Rituxan	79

Incidence of Non-relapse Mortality

(NCT01161628)
Timeframe: 2 years

Intervention	percentage of patients (Number)
Rituxan	21

Incidence of Overall Survival

(NCT01161628)
Timeframe: 2 years

Intervention	percentage of patients (Number)
Rituxan	82

Rate of Complete Response of cGVHD to Treatment.

(NCT01161628)
Timeframe: 2 years

Intervention	percentage of patients (Number)
Rituxan	84

Rate of Overall Response of cGVHD to Treatment

(NCT01161628)
Timeframe: 2 years

Intervention	percentage of patients (Number)
Rituxan	88

Rate of Partial Response of cGVHD to Treatment

(NCT01161628)
Timeframe: 2 years

Intervention	percentage of patients (Number)
Rituxan	5

Requirement for Systemic Corticosteroid Use

(NCT01161628)
Timeframe: 2 years

Intervention	participants (Number)
Rituxan	20

Time to Immunosuppression Withdrawal

(NCT01161628)
Timeframe: 2 years

Intervention	days (Median)
Rituxan	300

Trials

2 trials available for prednisone and Orthopedic Disorders

Article	Year
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, Jul-15, Volume: 108, Issue:2 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Chronic Diseas	2006
Use of supplemental steroids in patients having orthopaedic operations. The Journal of bone and joint surgery. American volume, 1995, Volume: 77, Issue:12 Topics: Adrenal Cortex Function Tests; Adrenal Insufficiency; Adult; Aged; Aged, 80 and over; Dose-Response	1995

Other Studies

5 other studies available for prednisone and Orthopedic Disorders

Article	Year
Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low-Dose Glucocorticoids and Prevention by Anti-Osteoporosis Medications. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:10 Topics: Bone Density; Female; Fractures, Bone; Glucocorticoids; Humans; Inflammation; Longitudinal Studies;	2023
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:2 Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch	2019
Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. Rheumatology (Oxford, England), 2004, Volume: 43, Issue:8 Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Syst	2004
Nudulo-cystic eruption with musculoskeletal pain. The Journal of family practice, 2007, Volume: 56, Issue:3 Topics: Acne Vulgaris; Adolescent; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio	2007
Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT? Bone marrow transplantation, 2001, Volume: 28, Issue:1 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined	2001